Autologous Matrix-induced Chondrogenesis - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509246933

Publication Date:

September 18, 2024

Pages:

112

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Autologous matrix-induced chondrogenesis (AMIC) is a surgical technique used to repair cartilage defects in the knee joint.
The global market for Autologous Matrix-induced Chondrogenesis was estimated to be worth US$ 103.9 million in 2023 and is forecast to a readjusted size of US$ 149.5 million by 2030 with a CAGR of 4.9% during the forecast period 2024-2030
The market for AMIC is driven by the growing prevalence of knee injuries and osteoarthritis, leading to a demand for advanced and minimally invasive cartilage repair techniques. The increasing focus on sports and physical activities further fuels the adoption of AMIC procedures.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Autologous Matrix-induced Chondrogenesis, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Autologous Matrix-induced Chondrogenesis by region & country, by Type, and by Application.
The Autologous Matrix-induced Chondrogenesis market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Autologous Matrix-induced Chondrogenesis.
麻豆原创 Segmentation
By Company
JRI Orthopaedics Ltd
BioTissue
Anika Therapeutics
B. Braun Melsungen
Arthro-Kinetics
Geistlich Pharma
CartiHeal
Matricel
Smith & Nephew
Zimmer Biomet Holdings
Segment by Type:
Hyaluronic Acid
Collagen
Polyethylene Glycol (PEG)
Poly Lactic-Co-Glycolic Acid (PGLA)
Segment by Application
Knees Joint
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Autologous Matrix-induced Chondrogenesis manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Autologous Matrix-induced Chondrogenesis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Autologous Matrix-induced Chondrogenesis in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Autologous Matrix-induced Chondrogenesis Product Introduction
1.2 Global Autologous Matrix-induced Chondrogenesis 麻豆原创 Size Forecast
1.3 Autologous Matrix-induced Chondrogenesis 麻豆原创 Trends & Drivers
1.3.1 Autologous Matrix-induced Chondrogenesis Industry Trends
1.3.2 Autologous Matrix-induced Chondrogenesis 麻豆原创 Drivers & Opportunity
1.3.3 Autologous Matrix-induced Chondrogenesis 麻豆原创 Challenges
1.3.4 Autologous Matrix-induced Chondrogenesis 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Autologous Matrix-induced Chondrogenesis Players Revenue Ranking (2023)
2.2 Global Autologous Matrix-induced Chondrogenesis Revenue by Company (2019-2024)
2.3 Key Companies Autologous Matrix-induced Chondrogenesis Manufacturing Base Distribution and Headquarters
2.4 Key Companies Autologous Matrix-induced Chondrogenesis Product Offered
2.5 Key Companies Time to Begin Mass Production of Autologous Matrix-induced Chondrogenesis
2.6 Autologous Matrix-induced Chondrogenesis 麻豆原创 Competitive Analysis
2.6.1 Autologous Matrix-induced Chondrogenesis 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Autologous Matrix-induced Chondrogenesis Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Autologous Matrix-induced Chondrogenesis as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Hyaluronic Acid
3.1.2 Collagen
3.1.3 Polyethylene Glycol (PEG)
3.1.4 Poly Lactic-Co-Glycolic Acid (PGLA)
3.2 Global Autologous Matrix-induced Chondrogenesis Sales Value by Type
3.2.1 Global Autologous Matrix-induced Chondrogenesis Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Autologous Matrix-induced Chondrogenesis Sales Value, by Type (2019-2030)
3.2.3 Global Autologous Matrix-induced Chondrogenesis Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Knees Joint
4.1.2 Other
4.2 Global Autologous Matrix-induced Chondrogenesis Sales Value by Application
4.2.1 Global Autologous Matrix-induced Chondrogenesis Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Autologous Matrix-induced Chondrogenesis Sales Value, by Application (2019-2030)
4.2.3 Global Autologous Matrix-induced Chondrogenesis Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Autologous Matrix-induced Chondrogenesis Sales Value by Region
5.1.1 Global Autologous Matrix-induced Chondrogenesis Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Autologous Matrix-induced Chondrogenesis Sales Value by Region (2019-2024)
5.1.3 Global Autologous Matrix-induced Chondrogenesis Sales Value by Region (2025-2030)
5.1.4 Global Autologous Matrix-induced Chondrogenesis Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Autologous Matrix-induced Chondrogenesis Sales Value, 2019-2030
5.2.2 North America Autologous Matrix-induced Chondrogenesis Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Autologous Matrix-induced Chondrogenesis Sales Value, 2019-2030
5.3.2 Europe Autologous Matrix-induced Chondrogenesis Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Autologous Matrix-induced Chondrogenesis Sales Value, 2019-2030
5.4.2 Asia Pacific Autologous Matrix-induced Chondrogenesis Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Autologous Matrix-induced Chondrogenesis Sales Value, 2019-2030
5.5.2 South America Autologous Matrix-induced Chondrogenesis Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Autologous Matrix-induced Chondrogenesis Sales Value, 2019-2030
5.6.2 Middle East & Africa Autologous Matrix-induced Chondrogenesis Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Autologous Matrix-induced Chondrogenesis Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Autologous Matrix-induced Chondrogenesis Sales Value
6.3 United States
6.3.1 United States Autologous Matrix-induced Chondrogenesis Sales Value, 2019-2030
6.3.2 United States Autologous Matrix-induced Chondrogenesis Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Autologous Matrix-induced Chondrogenesis Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Autologous Matrix-induced Chondrogenesis Sales Value, 2019-2030
6.4.2 Europe Autologous Matrix-induced Chondrogenesis Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Autologous Matrix-induced Chondrogenesis Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Autologous Matrix-induced Chondrogenesis Sales Value, 2019-2030
6.5.2 China Autologous Matrix-induced Chondrogenesis Sales Value by Type (%), 2023 VS 2030
6.5.3 China Autologous Matrix-induced Chondrogenesis Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Autologous Matrix-induced Chondrogenesis Sales Value, 2019-2030
6.6.2 Japan Autologous Matrix-induced Chondrogenesis Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Autologous Matrix-induced Chondrogenesis Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Autologous Matrix-induced Chondrogenesis Sales Value, 2019-2030
6.7.2 South Korea Autologous Matrix-induced Chondrogenesis Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Autologous Matrix-induced Chondrogenesis Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Autologous Matrix-induced Chondrogenesis Sales Value, 2019-2030
6.8.2 Southeast Asia Autologous Matrix-induced Chondrogenesis Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Autologous Matrix-induced Chondrogenesis Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Autologous Matrix-induced Chondrogenesis Sales Value, 2019-2030
6.9.2 India Autologous Matrix-induced Chondrogenesis Sales Value by Type (%), 2023 VS 2030
6.9.3 India Autologous Matrix-induced Chondrogenesis Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 JRI Orthopaedics Ltd
7.1.1 JRI Orthopaedics Ltd Profile
7.1.2 JRI Orthopaedics Ltd Main Business
7.1.3 JRI Orthopaedics Ltd Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
7.1.4 JRI Orthopaedics Ltd Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2019-2024)
7.1.5 JRI Orthopaedics Ltd Recent Developments
7.2 BioTissue
7.2.1 BioTissue Profile
7.2.2 BioTissue Main Business
7.2.3 BioTissue Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
7.2.4 BioTissue Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2019-2024)
7.2.5 BioTissue Recent Developments
7.3 Anika Therapeutics
7.3.1 Anika Therapeutics Profile
7.3.2 Anika Therapeutics Main Business
7.3.3 Anika Therapeutics Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
7.3.4 Anika Therapeutics Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2019-2024)
7.3.5 B. Braun Melsungen Recent Developments
7.4 B. Braun Melsungen
7.4.1 B. Braun Melsungen Profile
7.4.2 B. Braun Melsungen Main Business
7.4.3 B. Braun Melsungen Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
7.4.4 B. Braun Melsungen Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2019-2024)
7.4.5 B. Braun Melsungen Recent Developments
7.5 Arthro-Kinetics
7.5.1 Arthro-Kinetics Profile
7.5.2 Arthro-Kinetics Main Business
7.5.3 Arthro-Kinetics Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
7.5.4 Arthro-Kinetics Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2019-2024)
7.5.5 Arthro-Kinetics Recent Developments
7.6 Geistlich Pharma
7.6.1 Geistlich Pharma Profile
7.6.2 Geistlich Pharma Main Business
7.6.3 Geistlich Pharma Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
7.6.4 Geistlich Pharma Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2019-2024)
7.6.5 Geistlich Pharma Recent Developments
7.7 CartiHeal
7.7.1 CartiHeal Profile
7.7.2 CartiHeal Main Business
7.7.3 CartiHeal Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
7.7.4 CartiHeal Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2019-2024)
7.7.5 CartiHeal Recent Developments
7.8 Matricel
7.8.1 Matricel Profile
7.8.2 Matricel Main Business
7.8.3 Matricel Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
7.8.4 Matricel Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2019-2024)
7.8.5 Matricel Recent Developments
7.9 Smith & Nephew
7.9.1 Smith & Nephew Profile
7.9.2 Smith & Nephew Main Business
7.9.3 Smith & Nephew Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
7.9.4 Smith & Nephew Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2019-2024)
7.9.5 Smith & Nephew Recent Developments
7.10 Zimmer Biomet Holdings
7.10.1 Zimmer Biomet Holdings Profile
7.10.2 Zimmer Biomet Holdings Main Business
7.10.3 Zimmer Biomet Holdings Autologous Matrix-induced Chondrogenesis Products, Services and Solutions
7.10.4 Zimmer Biomet Holdings Autologous Matrix-induced Chondrogenesis Revenue (US$ Million) & (2019-2024)
7.10.5 Zimmer Biomet Holdings Recent Developments
8 Industry Chain Analysis
8.1 Autologous Matrix-induced Chondrogenesis Industrial Chain
8.2 Autologous Matrix-induced Chondrogenesis Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Autologous Matrix-induced Chondrogenesis Sales Model
8.5.2 Sales Channel
8.5.3 Autologous Matrix-induced Chondrogenesis Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

JRI Orthopaedics Ltd
BioTissue
Anika Therapeutics
B. Braun Melsungen
Arthro-Kinetics
Geistlich Pharma
CartiHeal
Matricel
Smith & Nephew
Zimmer Biomet Holdings

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.